血清miR-485、miR-205-5p水平与卵巢癌患者化疗效果的相关性分析

摘要/Abstract

摘要： 目的探讨血清miR-485、miR-205-5p水平与卵巢癌（OC）患者化疗效果的相关性。方法回顾性选取2020年12月~2023年12月南阳市中心医院收治的114例OC患者为研究对象,依照化疗4个周期后效果分为缓解组（59例）、稳定组（31例）、恶化组（24例）。比较3组化疗前、化疗2个周期后、化疗4个周期后血清miR-485、miR-205-5p水平并分析相关性,分析血清miR-485、miR-205-5p水平联合检测对OC患者化疗效果的预测价值。结果恶化组血清miR-485水平比稳定组、缓解组低,且稳定组比缓解组低（P<0.05）,恶化组血清miR-205-5p水平比稳定组、缓解组高,且稳定组比缓解组高,差异有统计学意义（P<0.05）;化疗前血清miR-485水平<化疗2个周期后<化疗4个周期后,血清miR-205-5p水平>化疗2个周期后>化疗4个周期后,差异有统计学意义（P<0.05）;血清miR-485与化疗效果呈负相关,血清miR-205-5p水平与化疗效果呈正相关,差异有统计学意义（P<0.05）;化疗2个周期后血清miR-485、miR-205-5p水平联合预测OC患者化疗结果恶化的受试者操作特征曲线（ROC）曲线下面积（AUC）为0.846,最佳诊断灵敏度为87.50%,特异度84.44%,差异有统计学意义（P<0.05）。结论血清miR-485、miR-205-5p水平与OC患者化疗效果密切相关,可为临床预测化疗效果提供有效参考。

关键词: miR-485, miR-205-5p, 卵巢癌, 化疗

Abstract: Objective To explore the correlation between the levels of serum miR-485 and miR-205-5p and the efficacy of chemotherapy in patients with ovarian cancer (OC). Methods A retrospective study was conducted on 114 patients with OC admitted to Nanyang Central Hospital from December 2020 to December 2023. These patients were divided into three groups based on the effect of chemotherapy after four cycles: remission group (59 cases), stable group (31 cases), and deterioration group (24 cases). The serum levels of miR-485 and miR-205-5p before chemotherapy, after two cycles of chemotherapy and after four cycles of chemotherapy were compared among the three groups, and the correlation was analyzed. The predictive value of combined detection of serum levels of miR-485 and miR-205-5p for chemotherapy effect in patients with OC was analyzed. Results The serum miR-485 level in the deterioration group was lower than that in the stable group and the remission group, and the stable group was lower than that in the remission group (P<0.05), the serum miR-205-5p level in the deterioration group was higher than that in the stable group and the remission group, and the stable group was higher than that in the remission group, the differences were statistically significant (P<0.05); serum miR-485 level before chemotherapy<after 2 cycles of chemotherapy<after 4 cycles of chemotherapy, serum miR-205-5p level before chemotherapy>after 2 cycles of chemotherapy>after 4 cycles of chemotherapy, the differences were statistically significant (P<0.05); Serum miR-485 level was negatively correlated with the effect of chemotherapy, and serum miR-205-5p level was positively correlated with the effect of chemotherapy, the differences were statistically significant (P<0.05); the area under the ROC curve (AUC) of serum levels of miR-485 and miR-205-5p combined to predict the deterioration of chemotherapy results in patients with OC after two cycles of chemotherapy was 0.846, and the best diagnostic sensitivity was 87.50%, specificity was 84.44%, the differences were statistically significant P<0.05). Conclusion The serum levels of miR-485 and miR-205-5p are closely related to the effect of chemotherapy in patients with OC, which can provide an effective reference for clinical prediction of chemotherapy effect.

Key words: miR-485, miR-205-5p, Ovarian cancer, Chemotherapy

中图分类号:

R737.31

王远航, 徐小晶, 雷雯, 孙勃. 血清miR-485、miR-205-5p水平与卵巢癌患者化疗效果的相关性分析[J]. 承德医学院学报, 2025, 42(1): 24-28.

WANG Yuan-hang, XU Xiao-jing, LEI Wen, SUN Bo. Correlation Analysis of Serum Levels of miR-485, miR-205-5p and Chemotherapy Effect in Patients with Ovarian Cancer[J]. Journal of Chengde Medical University, 2025, 42(1): 24-28.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I1/24

参考文献

[1] 袁华,李宁,吴令英. 卵巢癌中同源重组修复基因逆转突变导致多腺苷二磷酸核糖聚合酶抑制剂耐药的研究进展[J]. 癌症进展,2022,20(9):875-879.
[2] 宓淑芳,张立梅,李沫,等. 贝伐珠单抗治疗铂耐药卵巢癌、输卵管癌、腹膜癌患者的临床研究[J]. 中国临床药理学杂志,2023,39(23):3379-3383.
[3] 张攀扬,何明敏,曾园媛,等. 高级别浆液性卵巢癌复发相关的潜在功能性关键miRNA-mRNA:基于生物信息学方法[J]. 南方医科大学学报,2023,43(1):8-16.
[4] 郑玉涛,邵烁鋆,薛林怡,等. 缺氧调节肺腺癌小鼠MDSCs来源外泌体携带的miRNA及其免疫抑制功能[J]. 免疫学杂志,2023,39(3):192-198,224.
[5] 邓森灵,兰代群,曹雅文,等. 上皮性卵巢癌患者血清miR-362和miR-485的表达水平及其与预后的相关性研究[J]. 现代检验医学杂志,2022,37(4):35-37,42.
[6] 程万里,刘鑫,任文俊,等. MicroRNA在肺腺癌表皮生长因子受体—酪氨酸激酶抑制剂耐药中的作用及其机制研究进展[J]. 山东医药,2022,62(15):94-98.
[7] 刘鑫,夏继珍,柳英兰. 循环血液外泌体miRNA在卵巢癌发生发展中作用及其诊断价值的研究进展[J]. 现代肿瘤医学,2022,30(12):2268-2272.
[8] 牛高丽,翟艳红,王虹,等. 子宫内膜异位症相关卵巢癌的临床特点及miRNA表达的研究进展[J]. 中国计划生育和妇产科,2021,13(6):14-18.
[9] 赵劼,黄超林. 黄芩苷通过上调miR-485抑制卵巢癌细胞增殖和侵袭[J]. 解剖科学进展,2023,29(5):541-544.
[10] 韩成美,柳梅,任维鑫,等. miR-485-5 p介导SOX5基因表达对肝细胞肝癌细胞活力及迁移侵袭的影响[J]. 安徽医科大学学报,2021,56(5):710-715.
[11] 马胜辉,崔雪琴,李建华,等. 结直肠癌组织miR-485-5p,miR-1207-3p和miR-590-3p水平表达与临床病理特征及生存的相关性研究[J]. 现代检验医学杂志,2022,37(3):16-20,32.
[12] Zhang H, Axinbai M, Zhao Y, et al.Bioinformatics analysis of ferroptosis-related genes and immune cell infiltration in non-alcoholic fatty liver disease[J]. Med Res, 2023, 28(1): 605.
[13] 刘秋颖,李晓妍,张亚云,等. miR-205-5p、PDCD5、Beclin1在子宫内膜癌组织中的表达及相关性研究[J]. 河北医科大学学报,2022,43(7):796-800,816.
[14] Huang X, Li Z, Zhang L, et al.miR-205-5p inhibits homocysteine-induced pulmonary microvascular endothelium dysfunction by targeting FOXO1[J]. Acta Biochim Biophys Sin (Shanghai), 2023, 55(9): 1456-1466.
[15] 张红梅,梁艳丽,席源,等. miR-205-5p在卵巢癌患者血清中的表达及其预后价值[J]. 中南医学科学杂志,2022,50(2):257-260.